X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs

By Robert Zirkelbach  |    July 12, 2017
Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the...   Read More

New data put medicine costs and spending in context

By Holly Campbell  |    June 26, 2017
We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to more effectively treat chronic diseases, like cancer and diabetes, which are the biggest...   Read More

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

By Kevin Haninger  |    June 14, 2017
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care...   Read More

Medicines have significantly increased chances of cancer survival around the globe

By Amey Sutkowski  |    May 24, 2017
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to...   Read More

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

By Holly Campbell  |    May 4, 2017
We have seen a deluge of data recently from government actuaries and pharmacy benefit managers showing a dramatic slowdown in medicine spending growth. And the QuintilesIMS Medicines Use and...   Read More

New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

By Holly Campbell  |    March 29, 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...   Read More

How innovative medicines are benefiting countries across the globe

By Mark Grayson  |    March 1, 2017
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...   Read More

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    February 17, 2017
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates,...   Read More

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates